PillPack, a full-service online pharmacy owned by Amazon.com (NASDAQ: AMZN), reached an agreement to settle a lawsuit alleging that it committed fraud in connection with its insulin pen dispensing practice.
Under the settlement, PillPack agreed to pay $5,616,136.85 to the United States and $175,522.55 to state governments. The total amount to resolve the fraud lawsuit is $5,791,659.40.
The online pharmacy also admitted and accepted accountability for some of its conduct alleged in the complaint.
In July 2019, whistleblowers also known as relators filed a complaint against Amazon and PillPack under the qui tam provisions of the False Claims Act and related state false claims and insurance fraud laws.
The whistleblowers alleged that PillPack engaged in a pattern of improperly billing government healthcare programs (GHPs) including Medicare, Medicaid, TRICARE, and the Federal Employees Health Benefits Program (FEHBP) for insulin pens dispensed to diabetic patients.
From April 2014 to November 2019, PillPack allegedly fraudulently submitted reimbursements for insulin pens that were more than what patients needed based on their prescriptions. During that period, the online pharmacy allegedly falsely under-reported the days-of-supply of insulin pens dispensed to patients.
